BioCentury
ARTICLE | Company News

Enchira, Maxygen genomics, proteomics news

November 12, 2001 8:00 AM UTC

The companies completed arbitration related to a breach-of-contract dispute following a 1997 development and license agreement (see BioCentury, March 12). An arbitrator ruled that MAXY is the exclusive owner of ENBC's Rachitt gene shuffling technology and barred ENBC from using, licensing or otherwise commercializing Rachitt or modifications of it until 2017. MAXY said it also was granted an injunction barring ENBC from using, licensing or otherwise commercializing high throughput screening technology based on MAXY technologies for three years and will be reimbursed by ENBC for its attorneys' fees and all costs of the arbitration. ...